CD34 and retinal degeneration: However, a phase 1 clinical trial has been initiated exploring the effect of autologous intravitreal BM CD34+ cell therapy in patients with vision loss from retinal degeneration.8 No adverse effects were noted to be associated with the cell therapy during the 6-month study follow-up.